Welcome to our dedicated page for HEMOGENYX PHARMACEUTICALS news (Ticker: HOPHF), a resource for investors and traders seeking the latest updates and insights on HEMOGENYX PHARMACEUTICALS stock.
Hemogenyx Pharmaceuticals plc (LSE:HEMO) is a biopharmaceutical group focused on developing new therapies and treatments for blood diseases. The company's Chimeric Bait Receptor platform shows promise in treating cancers like Non-Hodgkin Lymphoma and solid tumors. Hemogenyx Pharmaceuticals utilizes Artificial Intelligence for protein structure simulations and mRNA synthesis to expedite R&D efforts. With recent FDA consents for Phase I trials of HEMO-CAR-T for AML, the company is advancing towards potentially life-saving treatments.
Hemogenyx Pharmaceuticals plc (LSE:HEMO)(OTC PINK:HOPHF) reported that Financial Controller Andrew Wright acquired 1,088,120 ordinary shares at an average price of 1.8288 pence per share, totaling £19,899.54. This purchase increases Wright's holding to 2,715,111 shares, approximately 0.50% of the company's issued capital. The transaction, disclosed under Market Abuse Regulation, occurred on May 18, 2021, on the London Stock Exchange. The company emphasizes compliance with regulations regarding insider information.
Hemogenyx Pharmaceuticals has announced the termination of its agreement with Mint Capital regarding the £8.1 million convertible loan notes issued on February 3, 2021. The company will redeem £1.6 million of these notes, while Mint Capital will sell £6.5 million worth to investors, who will convert them into ordinary shares at 1.5 pence each. Following the conversion, no convertible loan notes will remain outstanding, allowing Hemogenyx to focus on advancing its clinical trials.
Hemogenyx Pharmaceuticals has announced the conversion of £500,000 in principal amount of Convertible Loan Notes, resulting in the issuance of 22,222,222 new ordinary shares at a conversion price of £0.0225 per share. This is set to take effect on May 17, 2021, with the total number of voting shares rising to 546,415,988 post-admission. The company has no immediate plans for further drawdowns from this Convertible Notes Facility. The new shares will share the same voting rights as existing shares.
Hemogenyx Pharmaceuticals has announced its final results for the year ended 31 December 2020, highlighting significant scientific advancements. Key achievements include the efficacy of HEMO-CAR-T cells against Acute Myeloid Leukemia, development of a new cell-based platform for treating emerging viral diseases, and collaborations with Eli Lilly and the University of Pennsylvania. Post-period, a Master Translational Agreement with the University was established, advancing HEMO-CAR-T towards clinical trials. The CEO emphasized the productivity and diversification of the company’s product pipeline.
Hemogenyx Pharmaceuticals plc (LSE:HEMO)(OTC PINK:HOPHF) has confirmed its total issued share capital as of April 30, 2021, consisting of 494,343,020 ordinary shares of 1 pence each, with no shares held in treasury. This total represents the number of voting rights available to shareholders and serves as a denominator for notifications regarding changes in shareholding under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Hemogenyx Pharmaceuticals announced the conversion of £900,000 in Convertible Loan Notes issued on February 3, 2021, into 29,850,746 new ordinary shares at a conversion price of £0.03015 each. Following the conversion, the company will have 524,193,766 ordinary shares in issue with voting rights. The admission of these new shares is expected on or around May 5, 2021. No immediate plans for further drawdowns from the facility have been indicated. This step is part of the company's ongoing efforts in developing treatments for blood and autoimmune diseases.
Hemogenyx Pharmaceuticals has received a conversion notice from Mint Capital Advisors for £950,000 worth of Convertible Loan Notes, which will lead to the issuance of 24,547,803 new ordinary shares at a conversion price of £0.0387 each. These shares will be admitted to trading on the London Stock Exchange, expected on April 22, 2021. Following the issuance, the total number of ordinary shares in circulation will reach 494,343,020. The company has no immediate plans for further drawdowns from the Convertible Notes Facility.
Hemogenyx Pharmaceuticals plc (OTC PINK:HOPHF) announced on March 31, 2021, that its total issued share capital comprises 454,509,503 ordinary shares of 1 pence each, with none held in treasury. This total establishes the number of voting rights available to shareholders, which they may use as a denominator for notifications regarding changes in their investment under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. The company emphasizes that all shares are fully issued and voting rights are in effect.
FAQ
What is the current stock price of HEMOGENYX PHARMACEUTICALS (HOPHF)?
What is the market cap of HEMOGENYX PHARMACEUTICALS (HOPHF)?
What is Hemogenyx Pharmaceuticals focused on?
What is the significance of the Chimeric Bait Receptor platform?
How does Hemogenyx Pharmaceuticals expedite its R&D efforts?
What recent FDA development has Hemogenyx Pharmaceuticals achieved?
